RECRUITING

The Dynamics of Human Atrial Fibrillation

Description

Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.

Study Overview

Study Details

Study overview

Atrial fibrillation (AF) is an enormous public health problem in the United States, affecting 2-5 million Americans and causing rapid heart beats, stroke, heart failure or death. In this project, the applicant will develop a novel framework to better understand human AF that builds on agreement between several concepts for the disease. The applicant will develop strategies to identify AF patients who will best respond to each of several therapies, to guide personalized therapy.

The Dynamics of Human Atrial Fibrillation

The Dynamics of Human Atrial Fibrillation

Condition
Atrial Fibrillation
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University, Stanford, California, United States, 94305

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * referred for ablation or Maze surgery at Stanford Medicine for persistent AF (i.e. which requires cardioversion to terminate and/or lasts \>7 days)
  • * Per our clinical practice and guidelines (Calkins et al., Heart Rhythm 2018), patients will have failed or be intolerant of \>or= 1 anti-arrhythmic drug. Patients after Maze surgery typically have failed prior endocardial ablation.
  • * active coronary ischemia or decompensated heart failure
  • * atrial or ventricular clot on trans-esophageal echocardiography
  • * pregnancy (to minimize fluoroscopic exposure)
  • * inability or unwillingness to provide informed consent
  • * rheumatic valve disease (results in a unique AF phenotype)
  • * thrombotic disease or venous filters
  • * prior chest surgery is a relative contraindication for Maze surgery

Ages Eligible for Study

22 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stanford University,

Study Record Dates

2026-12-30